High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up - Villa, L L; Costa, R L R; Petta, C A; Andrade, R P; Paavonen, J; Iversen, O-E; Olsson, S-E; Høye, J; Steinwall, M; Riis-Johannessen, G; Andersson-Ellstrom, A; Elfgren, K; et al. (British journal of cancer, 2006)
Keywords: Adolescent; Adult; Alphapapillomavirus - immunology; antibodies; Antibodies, Viral - blood; Biomedical and Life Sciences; Biomedicine; cancer; Cancer and Oncology; Cancer och onkologi; Cancer Research; cervical; cervical intraepithelial neoplasia (CIN); Cervical Intraepithelial Neoplasia - prevention & control; cervical-cancer; classification; Clinical Medicine; Clinical Study; clinical trial; Condylomata Acuminata - prevention & control; controlled-trial; Double-Blind Method; Drug Resistance; Epidemiology; Female; Follow-Up Studies; genital warts; hpv; Human papillomavirus; Humans; Incidence; infection; intraepithelial neoplasia; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Molecular Medicine; Oncology; Papillomavirus Infections - epidemiology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - immunology; Papillomavirus Vaccines - therapeutic use; population; prophylactic vaccine; recurrent respiratory papillomatosis; Uterine Cervical Dysplasia - prevention & control; Uterine Cervical Neoplasms - prevention & control; Vaginal Smears; Virion - immunology; virus-like particles; genital warts; clinical trial; virus-like particles; cervical intraepithelial neoplasia (CIN); human papillomavirus; prophylactic vaccine; cervical cancer